Changes
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make BPC-157 on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make epitalon on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make KPV on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make MOTS-c on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make semax on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
The US health department published a draft policy under which it would not act against pharmacies that make TB-500 on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
- Legal
WADA approved its list of banned substances for 2027, in force from 1 January 2027. Semaglutide and tirzepatide stay allowed.
- Legal
FDA staff proposed that pharmacies should not make BPC-157. FDA advisers voted 8 to 6, with one abstention, to allow it. The vote is not binding.
- Legal
The FDA announced a review of BPC-157 and other peptides. A law firm reports that they left a US list of substances raising concerns after requests were withdrawn. This does not mean pharmacies may legally make them.